{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:12:49Z","timestamp":1789913569576,"version":"4.0.1"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000957","name":"Alzheimer's Disease Association","doi-asserted-by":"publisher","award":["IIRG-13-284238"],"award-info":[{"award-number":["IIRG-13-284238"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"NIA","doi-asserted-by":"publisher","award":["R21AG045757"],"award-info":[{"award-number":["R21AG045757"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"NIA","doi-asserted-by":"publisher","award":["RO1AG-022476"],"award-info":[{"award-number":["RO1AG-022476"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ignition Award"},{"name":"BU ADC pilot grant 2011"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.neuropharm.2017.03.030","type":"journal-article","created":{"date-parts":[[2017,3,28]],"date-time":"2017-03-28T15:47:10Z","timestamp":1490716030000},"page":"170-181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Amylin receptor ligands reduce the pathological cascade of Alzheimer's disease"],"prefix":"10.1016","volume":"119","author":[{"given":"Haihao","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiehua","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Wallack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob M.","family":"Hooker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Kowall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiushan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thor D.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Wolozin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Qiao","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2017.03.030_bib1","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.neurobiolaging.2013.10.076","article-title":"Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition","volume":"35","author":"Adler","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2017.03.030_bib2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1369\/jhc.6A7156.2007","article-title":"Actin-binding proteins coronin-1a and IBA-1 are effective microglial markers for immunohistochemistry","volume":"55","author":"Ahmed","year":"2007","journal-title":"J.\u00a0Histochem. Cytochem. Off. J. Histochem. Soc."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib3","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0197-4580(00)00173-1","article-title":"Quantitative neurohistological features of frontotemporal degeneration","volume":"21","author":"Arnold","year":"2000","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2017.03.030_bib4","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0196-9781(98)00018-7","article-title":"Differential permeability of the blood-brain barrier to two pancreatic peptides: insulin and amylin","volume":"19","author":"Banks","year":"1998","journal-title":"Peptides"},{"key":"10.1016\/j.neuropharm.2017.03.030_bib5","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/0024-3205(95)02197-Q","article-title":"Permeability of the blood-brain barrier to amylin","volume":"57","author":"Banks","year":"1995","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib6","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0014-5793(93)80849-P","article-title":"Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5","volume":"336","author":"Baumann","year":"1993","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib7","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.2337\/diabetes.52.9.2315","article-title":"An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures","volume":"52","author":"Bennett","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.neuropharm.2017.03.030_bib8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1146\/annurev-pharmtox-011613-135932","article-title":"Emerging therapeutics for Alzheimer's disease","volume":"54","author":"Chiang","year":"2014","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1124\/mol.56.1.235","article-title":"Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product","volume":"56","author":"Christopoulos","year":"1999","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib10","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.cell.2009.11.014","article-title":"Reduced IGF-1 signaling delays age-associated proteotoxicity in mice","volume":"139","author":"Cohen","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2017.03.030_bib11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/j.1552-4604.1996.tb04147.x","article-title":"Pharmacokinetics and pharmacodynamics of AC137 (25,28,29 tripro-amylin, human) after intravenous bolus and infusion doses in patients with insulin-dependent diabetes","volume":"36","author":"Colburn","year":"1996","journal-title":"J.\u00a0Clin. Pharmacol."},{"issue":"Pt 1","key":"10.1016\/j.neuropharm.2017.03.030_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1042\/bj3380015","article-title":"Rat-2 fibroblasts express specific adrenomedullin receptors, but not calcitonin-gene-related-peptide receptors, which mediate increased intracellular cAMP and inhibit mitogen-activated protein kinase activity","volume":"338","author":"Coppock","year":"1999","journal-title":"Biochem. J."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib13","doi-asserted-by":"crossref","first-page":"e59113","DOI":"10.1371\/journal.pone.0059113","article-title":"Proteolytically inactive insulin-degrading enzyme inhibits amyloid formation yielding non-neurotoxic abeta peptide aggregates","volume":"8","author":"de Tullio","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.neuropharm.2017.03.030_bib14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A\u00a0phase 3 trial of semagacestat for treatment of Alzheimer's disease","volume":"369","author":"Doody","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib15","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.nbd.2008.08.001","article-title":"Microglia, amyloid, and cognition in Alzheimer's disease: an [11C](R)PK11195-PET and [11C]PIB-PET study","volume":"32","author":"Edison","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib16","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1100\/tsw.2001.23","article-title":"Amylin: localization, effects on cerebral arteries and on local cerebral blood flow in the cat","volume":"1","author":"Edvinsson","year":"2001","journal-title":"Sci. World J."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib17","doi-asserted-by":"crossref","first-page":"18820","DOI":"10.1074\/jbc.M111.331181","article-title":"Amyloid beta (Abeta) peptide directly activates amylin-3 receptor subtype by triggering multiple intracellular signaling pathways","volume":"287","author":"Fu","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib18","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s001250051364","article-title":"Islet amyloid polypeptide in the islets of Langerhans: friend or foe?","volume":"43","author":"Gebre-Medhin","year":"2000","journal-title":"Diabetologia"},{"key":"10.1016\/j.neuropharm.2017.03.030_bib19","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Sci. (New York, NY)"},{"key":"10.1016\/j.neuropharm.2017.03.030_bib20","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1124\/pr.115.010629","article-title":"Amylin: pharmacology, physiology, and clinical potential","volume":"67","author":"Hay","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib21","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1126\/science.aad8373","article-title":"Complement and microglia mediate early synapse loss in Alzheimer mouse models","volume":"352","author":"Hong","year":"2016","journal-title":"Sci. (New York, NY)"},{"key":"10.1016\/j.neuropharm.2017.03.030_bib22","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1006\/bbrc.1996.1112","article-title":"A\u00a0novel gene iba1 in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage","volume":"224","author":"Imai","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1586\/eci.11.93","article-title":"Solanezumab for the treatment of mild-to-moderate Alzheimer's disease","volume":"8","author":"Imbimbo","year":"2012","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib24","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1161\/01.STR.32.5.1208","article-title":"Enhanced expression of Iba1, ionized calcium-binding adapter molecule 1, after transient focal cerebral ischemia in rat brain","volume":"32","author":"Ito","year":"2001","journal-title":"Stroke; a J. Cereb. Circ."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib25","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/ana.23956","article-title":"Amylin deposition in the brain: a second amyloid in Alzheimer disease?","volume":"74","author":"Jackson","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib26","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ajpath.2010.11.022","article-title":"Actions of beta-amyloid protein on human neurons are expressed through the amylin receptor","volume":"178","author":"Jhamandas","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib27","doi-asserted-by":"crossref","first-page":"17401","DOI":"10.1523\/JNEUROSCI.3028-12.2012","article-title":"Beta amyloid-induced depression of hippocampal long-term potentiation is mediated through the amylin receptor","volume":"32","author":"Kimura","year":"2012","journal-title":"J.\u00a0Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib28","doi-asserted-by":"crossref","first-page":"179ra142","DOI":"10.1126\/scitranslmed.3005681","article-title":"Amyloid fibrils composed of hexameric peptides attenuate neuroinflammation","volume":"5","author":"Kurnellas","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3233\/JAD-2003-5207","article-title":"Cdk5: one of the links between senile plaques and neurofibrillary tangles?","volume":"5","author":"Lee","year":"2003","journal-title":"J.\u00a0Alzheimer's Dis. JAD"},{"key":"10.1016\/j.neuropharm.2017.03.030_bib30","doi-asserted-by":"crossref","first-page":"a006437","DOI":"10.1101\/cshperspect.a006437","article-title":"Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets","volume":"1","author":"Lee","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib31","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.febslet.2008.05.006","article-title":"Human but not rat amylin shares neurotoxic properties with Abeta42 in long-term hippocampal and cortical cultures","volume":"582","author":"Lim","year":"2008","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1463-1326.2012.01670.x","article-title":"The interaction of amylin with other hormones in the control of eating","volume":"15","author":"Lutz","year":"2013","journal-title":"Diabetes, Obes. Metab."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib33","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3389\/fnins.2015.00216","article-title":"Amylin at the interface between metabolic and neurodegenerative disorders","volume":"9","author":"Lutz","year":"2015","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/156720507779939850","article-title":"G\u00a0protein-coupled receptor signaling complexity in neuronal tissue: implications for novel therapeutics","volume":"4","author":"Maudsley","year":"2007","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib35","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1111\/j.1471-4159.1993.tb07480.x","article-title":"Neurotoxicity of human amylin in rat primary hippocampal cultures: similarity to Alzheimer's disease amyloid-beta neurotoxicity","volume":"61","author":"May","year":"1993","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib36","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/30666","article-title":"RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor","volume":"393","author":"McLatchie","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2017.03.030_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2016.02.034","article-title":"Amylin-mediated control of glycemia, energy balance, and cognition","author":"Mietlicki-Baase","year":"2016","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib38","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1021\/bi981658g","article-title":"Effects of sequential proline substitutions on amyloid formation by human amylin20-29","volume":"38","author":"Moriarty","year":"1999","journal-title":"Biochem. (Mosc)"},{"key":"10.1016\/j.neuropharm.2017.03.030_bib39","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1210\/mend-3-11-1775","article-title":"Human islet amyloid polypeptide gene: complete nucleotide sequence, chromosomal localization, and evolutionary history","volume":"3","author":"Nishi","year":"1989","journal-title":"Mol. Endocrinol. Baltim. Md)"},{"key":"10.1016\/j.neuropharm.2017.03.030_bib40","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1055\/s-2007-978867","article-title":"Plasma amylin immunoreactivity and insulin resistance in insulin resistant relatives of patients with non-insulin-dependent diabetes mellitus","volume":"30","author":"Nyholm","year":"1998","journal-title":"Horm. Metab. Res.\u00a0= Horm.- Stoffwechs.\u00a0= Horm. metab."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib41","doi-asserted-by":"crossref","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","article-title":"Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation","volume":"26","author":"Oakley","year":"2006","journal-title":"J.\u00a0Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib42","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0896-6273(03)00434-3","article-title":"Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction","volume":"39","author":"Oddo","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2017.03.030_bib43","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.peptides.2007.06.011","article-title":"Comparison of the effects of chronic central administration and chronic peripheral administration of islet amyloid polypeptide on food intake and meal pattern in the rat","volume":"28","author":"Olsson","year":"2007","journal-title":"Peptides"},{"key":"10.1016\/j.neuropharm.2017.03.030_bib44","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1084\/jem.5.4.397","article-title":"On the relation of chronic interstitial pancreatitis to the Islands of Langerhans and to diabetes melutus","volume":"5","author":"Opie","year":"1901","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib45","article-title":"Effect of active Abeta immunotherapy on neurons in human Alzheimer's disease","author":"Paquet","year":"2014","journal-title":"J.\u00a0Pathol."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib46","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1463-1326.2010.01201.x","article-title":"Safety of pramlintide added to mealtime insulin in patients with type 1 or type 2 diabetes: a large observational study","volume":"12","author":"Pencek","year":"2010","journal-title":"Diabetes, Obes. Metab."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib47","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/hmg\/ddh083","article-title":"CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation","volume":"13","author":"Petrucelli","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib48","doi-asserted-by":"crossref","DOI":"10.3233\/JAD-140210","article-title":"Positive association between plasma amylin and cognition in a homebound elderly population","author":"Qiu","year":"2014","journal-title":"J.\u00a0Alzheimer's Dis. JAD"},{"key":"10.1016\/j.neuropharm.2017.03.030_bib49","doi-asserted-by":"crossref","first-page":"32730","DOI":"10.1074\/jbc.273.49.32730","article-title":"Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation","volume":"273","author":"Qiu","year":"1998","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib50","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fnagi.2014.00186","article-title":"Amylin and its analogs: a friend or foe for the treatment of Alzheimer's disease?","volume":"6","author":"Qiu","year":"2014","journal-title":"Front. aging Neurosci."},{"issue":"Pt 4","key":"10.1016\/j.neuropharm.2017.03.030_bib51","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1242\/jcs.93.4.623","article-title":"Differential expression of membrane sialoglycoproteins in exudate and resident mouse peritoneal macrophages","volume":"93","author":"Rabinowitz","year":"1989","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib52","article-title":"Genome-wide interaction study of brain beta-amyloid burden and cognitive impairment in Alzheimer's disease","author":"Roostaei","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.03.030_bib53","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0376-8716(98)00067-2","article-title":"G\u00a0protein-coupled receptor (GPCR) trafficking in the central nervous system: relevance for drugs of abuse","volume":"51","author":"Roth","year":"1998","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib54","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1476-5381.2011.01537.x","article-title":"GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities","volume":"166","author":"Roth","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib55","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/MED.0b013e32835b896f","article-title":"Amylin and the regulation of appetite and adiposity: recent advances in receptor signaling. neurobiology and pharmacology. GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities","volume":"20","author":"Roth","year":"2013","journal-title":"Curr. Opin. Endocrinol. Diabetes, Obes."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib56","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1440-1827.1996.tb03528.x","article-title":"The immunophenotype of perivascular cells in the human brain","volume":"46","author":"Sasaki","year":"1996","journal-title":"Pathol. Int."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib57","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.drudis.2008.12.009","article-title":"Modulating receptor function through RAMPs: can they represent drug targets in themselves?","volume":"14","author":"Sexton","year":"2009","journal-title":"Drug Discov. today"},{"key":"10.1016\/j.neuropharm.2017.03.030_bib58","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/nature05143","article-title":"Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism","volume":"443","author":"Shen","year":"2006","journal-title":"Nature"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.neuropharm.2017.03.030_bib59","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1007\/s10875-014-0034-3","article-title":"Janus faces of amyloid proteins in neuroinflammation","volume":"34","author":"Steinman","year":"2014","journal-title":"J.\u00a0Clin. Immunol."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib60","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00401-009-0556-6","article-title":"Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease","volume":"118","author":"Streit","year":"2009","journal-title":"Acta Neuropathol. Berl."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib61","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nrn2977","article-title":"The role of G protein-coupled receptors in the pathology of Alzheimer's disease","volume":"12","author":"Thathiah","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib62","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1210\/en.2010-0590","article-title":"Enhanced amylin-mediated body weight loss in estradiol-deficient diet-induced obese rats","volume":"151","author":"Trevaskis","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2017.03.030_bib63","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/371419a0","article-title":"p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5","volume":"371","author":"Tsai","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2017.03.030_bib64","first-page":"1029","article-title":"Activity and expression pattern of cyclin-dependent kinase 5 in the embryonic mouse nervous system","volume":"119","author":"Tsai","year":"1993","journal-title":"Dev. Camb. Engl."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib65","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3233\/JAD-160677","article-title":"Amylin treatment reduces neuroinflammation and ameliorates abnormal patterns of gene expression in the cerebral cortex of an Alzheimer's disease mouse model","volume":"56","author":"Wang","year":"2017","journal-title":"J.\u00a0Alzheimer's Dis. JAD"},{"key":"10.1016\/j.neuropharm.2017.03.030_bib66","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1097\/00005344-199512000-00012","article-title":"Amylin-induced relaxation of the perfused mesenteric arterial bed: meditation by calcitonin gene-related peptide receptors","volume":"26","author":"Westfall","year":"1995","journal-title":"J.\u00a0Cardiovasc Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib67","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1054-3589(05)52017-9","article-title":"Central nervous system and other effects","volume":"52","author":"Young","year":"2005","journal-title":"Adv. Pharmacol. (San Diego, Calif)"},{"key":"10.1016\/j.neuropharm.2017.03.030_bib68","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.neuropharm.2016.07.008","article-title":"Multiple target of hAmylin on rat primary hippocampal neurons","volume":"113","author":"Zhang","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.03.030_bib69","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/mp.2014.17","article-title":"Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer's disease","volume":"20","author":"Zhu","year":"2015","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.03.030_bib70","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1093\/brain\/awt210","article-title":"Inflammatory components in human Alzheimer's disease and after active amyloid-beta42 immunization","volume":"136","author":"Zotova","year":"2013","journal-title":"Brain a J. neurol."},{"key":"10.1016\/j.neuropharm.2017.03.030_bib71","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2990.2010.01156.x","article-title":"Microglial alterations in human Alzheimer's disease following Abeta42 immunization","volume":"37","author":"Zotova","year":"2011","journal-title":"Neuropathol. Appl. Neurobiol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817301211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817301211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T23:59:23Z","timestamp":1658879963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390817301211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":71,"alternative-id":["S0028390817301211"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.03.030","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amylin receptor ligands reduce the pathological cascade of Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.03.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}